AstraZeneca in two more Seroquel XR patent settlements; Actavis outlines South America aims
In further patent settlements in the USA, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has now announced agreements with two more companies - Accord Healthcare and its Indian parent company Intas Pharmaceuticals - relating to Accord’s proposed generic copy of its blockbuster antipsychotic drug Seroquel XR (quetiapine, extended release).
The agreement, or pay-for-delay deal, settles the patent infringement litigation filed by AstraZeneca following Accord's submission to the US Food and Drug Administration of an Abbreviated New Drug Application for a generic Seroquel XR. Under the deal, Accord does not dispute that the patent asserted by AstraZeneca in the US patent litigation is valid and enforceable.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze